Connor, Clark & Lunn Investment Management (CC&L)’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $455K | Buy |
42,994
+8,573
| +25% | +$90.7K | ﹤0.01% | 1282 |
|
|
2025
Q1 | $517K | Sell |
34,421
-6,984
| -17% | -$105K | ﹤0.01% | 1136 |
|
|
2024
Q4 | $682K | Sell |
41,405
-16,201
| -28% | -$267K | ﹤0.01% | 1060 |
|
|
2024
Q3 | $1.42M | Sell |
57,606
-1,212
| -2% | -$29.9K | 0.01% | 766 |
|
|
2024
Q2 | $1.49M | Sell |
58,818
-1,266
| -2% | -$32.1K | 0.01% | 742 |
|
|
2024
Q1 | $1.53M | Buy |
60,084
+7,442
| +14% | +$189K | 0.01% | 750 |
|
|
2023
Q4 | $1.19M | Buy |
52,642
+512
| +1% | +$11.6K | 0.01% | 811 |
|
|
2023
Q3 | $971K | Buy |
52,130
+5,505
| +12% | +$103K | 0.01% | 831 |
|
|
2023
Q2 | $1.21M | Buy |
46,625
+30,627
| +191% | +$796K | 0.01% | 743 |
|
|
2023
Q1 | $459K | Buy |
+15,998
| New | +$459K | ﹤0.01% | 910 |
|
|
2016
Q1 | – | Sell |
-7,500
| Closed | -$286K | – | 827 |
|
|
2015
Q4 | $286K | Buy |
+7,500
| New | +$286K | ﹤0.01% | 638 |
|
|
2015
Q1 | – | Sell |
-8,800
| Closed | -$359K | – | 566 |
|
|
2014
Q4 | $359K | Sell |
8,800
-17,900
| -67% | -$730K | ﹤0.01% | 437 |
|
|
2014
Q3 | $979K | Sell |
26,700
-3,800
| -12% | -$139K | 0.01% | 309 |
|
|
2014
Q2 | $1.51M | Sell |
30,500
-14,600
| -32% | -$720K | 0.01% | 276 |
|
|
2014
Q1 | $2.05M | Buy |
45,100
+15,900
| +54% | +$721K | 0.02% | 272 |
|
|
2013
Q4 | $1.18M | Buy |
+29,200
| New | +$1.18M | 0.01% | 339 |
|